Orbapin 5 mg+40 mg (Tablet)
Unit Price: ৳ 20.00 (3 x 10: ৳ 600.00)
Strip Price: ৳ 200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Amlodipine besilate olmesartan medoxomil |
| Company | Acme laboratories ltd |
| Also available as |
Indications
- Treatment of hypertension alone or with other antihypertensive agents
- Lowering blood pressure
- Initial therapy for patients likely to need multiple antihypertensive agents
- Individualized decision for combination therapy based on baseline blood pressure
- Variation of individual blood pressure goals
Pharmacology
- Amlodipine as a dihydropyridine calcium channel blocker
- Greater effect on vascular smooth muscle cells than on cardiac muscle cells
- Peripheral arterial vasodilator effect of Amlodipine
- Blocking of vasoconstrictor and aldosterone-secreting effects of angiotensin II by Olmesartan Medoxomil
- Reversible, competitive inhibition of the AT1 receptor by Olmesartan Medoxomil
Dosage & Administration
- Substitution of individually titrated components
- Increased amounts of Amlodipine or Olmesartan Medoxomil as needed
- Initial therapy with 5/20 mg once daily for 1 to 2 weeks
- Titration up to a maximum of 10/40 mg once daily
- Recommended starting dose of 2.5 mg Amlodipine in patients 75 years or older
Interaction
- Possible attenuation of antihypertensive effect by NSAIDs including selective COX-2 inhibitors
- Close monitoring of blood pressure, renal function, and electrolytes in patients on combination therapy
Contraindications
- Cannot be co-administered with Aliskiren in patients with diabetes
Side Effects
- Peripheral edema
- Headache
- Flushing
- Dizziness
- Potential to cause sprue-like enteropathy
Pregnancy & Lactation
- Pregnancy Category D
- Avoid use in 2nd and 3rd trimester to prevent fetal death
- Discontinuation of combination when pregnancy is detected
- Potential excretion of the drug in human milk
- Consideration of adverse effects on the nursing infant
Precautions & Warnings
- Use with caution in volume- or salt-depleted patients
- Caution in patients with severe aortic stenosis
- Risk of increased frequency, duration, or severity of angina or acute MI in patients with severe obstructive coronary artery disease
Use in Special Populations
- No established safety and effectiveness in pediatric patients
- No overall differences in safety or effectiveness observed between elderly and younger subjects
- Lack of studies in patients with renal impairment
- Initial therapy not recommended in hepatically impaired patients
Overdose Effects
- No information available on overdose effects in humans
Therapeutic Class
- Combined antihypertensive preparations
Storage Conditions
- Storage temperature not to exceed 30°C
- Protection from light
- Keep out of the reach of children